Are We Avoiding the Issue of Pruritus in Primary Biliary Cholangitis and What’s in the Pipeline of Therapy?
January 12, 2024
January 12, 2025
This activity is jointly provided by P2P Syncro and Postgraduate Institute for Medicine.
This activity is supported by an independent educational grant from GSK.
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit™
- Nurses — 1.0 Contact Hour
- Physician Assistants — 1.0 CE Credit
- Pharmacists — 1.0 Contact Hour
Healthcare providers in gastroenterology, hepatology, internal medicine, family medicine, dermatology, rheumatology, and endocrinology who are involved in the diagnosis of pruritus and the care of patients with primary biliary cholangitis.
Itch is common and can be severe in primary biliary cholangitis (PBC). However, itch is not evaluated by physicians in 70% of the patients with PBC pruritus. Only 15% of physicians who treat PBC list pruritus as a medical problem. This CME program will address the issue, discuss solutions, and explore emerging treatment options.
Upon completion of this activity, participants should be better able to:
- Recognize that pruritis is common in PBC and the burden that patients carry from itch is significant.
- Inquire about pruritis in every patient’s visit and evaluate the cause and severity of itch.
- Discuss current treatment for PBC itch, emerging therapies, and the option of participating in clinical trials.
Kris V. Kowdley, MD
Dr. Kris Kowdley is a hepatologist at Washington State University and the Director of Liver Institute Northwest, Seatle, WA. Dr. Kowdley is an internationally recognized leader in the field of hepatology and has authored more than 400 articles. He is the lead investigator of a Phase 3 clinical trial investigating a novel therapy for primary biliary cholangitis.
Raj Vuppalanchi, MD
Dr. Raj Vuppalanchi is the Director of Clinical Hepatology at IU Health and Professor of Medicine at Indiana University School of Medicine. Dr. Vuppalanchi is trained in both gastroenterology-hepatology and clinical pharmacology. He has published extensively on various aspects of liver disease. He is the lead investigator of a clinical trial that studied a PPAR agonist in the treatment of primary biliary cholangitis.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and P2P Syncro. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - JA4008162-9999-24-012-H01-P. Type of Activity: Knowledge
Continuing Physician Assistant Education
Postgraduate Institute for Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until January 12, 2025. PAs should only claim credit commensurate with the extent of their participation.
Disclosures of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
- Kris Kowdley, MD
- Consulting: Calliditas, CymaBay, Genfit, Gilead, Inipharm, Intercept, Madrigal, Mirum, NGM, Pliant, and 89Bio
- Research support: Ipsen, CymaBay, Genfit, Gilead, GSK, High Tide, Hanmi, Intercept, Madrigal, Mirum, NGM, Pfizer, Pliant, Viking, and 89Bio
- Stock options: Inipharm
- Patent Holder/Royaltie: UpToDate
- Speaker Bureau: AbbVie, Gilead, Intercept
- Raj Vuppalanchi, MD
- Consulting: Echosens
- Research support: Zydus Therapeutics Inc, Eli Lilly, Astra Zeneca, Galectin Therpeutics, Takeda -- Institutional grants for clinical trial participation
The PIM planners and others have nothing to disclose. The P2P Syncro planners and others have nothing to disclose.
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME/CE information and faculty disclosures.
- Participate in the online activity.
- Submit the evaluation form.
Certificates will be emailed to the participant.
For Pharmacists: Upon completion of the online evaluation, your credit will be submitted to CPE Monitor. Pharmacists have up to thirty (30) days to complete the evaluation and claim credit. Please check your NABP account within thirty (30) days to make sure the credit has posted.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
Postgraduate Institute for Medicine (PIM) requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions please contact: [email protected].